Burden of systemic lupus erythematosus in clinical practice: baseline data from the SLE Prospective Observational Cohort Study (SPOCS) by interferon gene signature

被引:9
|
作者
Arnaud, Laurent [1 ,2 ]
Furie, Richard [3 ]
Morand, Eric F. [4 ]
Aringer, Martin [5 ,6 ]
Peschken, Christine [7 ]
Desta, Barnabas [8 ]
Rapsomaniki, Eleni [9 ]
Hedberg, Jonatan [10 ]
Knagenhjelm, Jacob [11 ]
Seo, Caroline [12 ]
Een, Tina Gruenfeld [8 ]
Sorrentino, Alessandro [12 ]
Tummala, Raj [8 ]
Stirnadel-Farrant, Heide A. [9 ]
Ding, Bo [10 ]
机构
[1] Univ Hosp Strasbourg, Dept Rheumatol, Strasbourg, France
[2] INSERM, French Natl Reference Ctr Rare Autoimmune Dis RESO, UMR S 1109, S 1109, Strasbourg, France
[3] Donald & Barbara Zucker Sch Med Hofstra Northwell, Great Neck, NY USA
[4] Monash Univ, Melbourne, Vic, Australia
[5] Tech Univ Dresden, Univ Neuropsychol Ctr, Dresden, Germany
[6] Tech Univ Dresden, Fac Med, Dresden, Germany
[7] Univ Manitoba, Rady Fac Hlth Sci, Winnipeg, MB, Canada
[8] AstraZeneca, BioPharmaceut R&D, Gaithersburg, MD USA
[9] AstraZeneca, BioPharmaceut Med, Cambridge, England
[10] AstraZeneca, BioPharmaceut Med, Gothenburg, Sweden
[11] AstraZeneca, Biopharmaceut R&D, Gothenburg, Sweden
[12] AstraZeneca, BioPharmaceut Med, Gaithersburg, MD USA
来源
LUPUS SCIENCE & MEDICINE | 2023年 / 10卷 / 02期
关键词
Autoimmune Diseases; Lupus Erythematosus; Systemic; Epidemiology; Glucocorticoids; DISEASE-ACTIVITY; I INTERFERON; MULTICENTER; ANIFROLUMAB; LYMPHOPENIA; MANAGEMENT;
D O I
10.1136/lupus-2023-001032
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective The longitudinal Systemic Lupus Erythematosus Prospective Observational Cohort Study (SPOCS) aims to assess SLE disease course overall and according to type I interferon 4 gene signature (IFNGS). Here, we describe SPOCS patient characteristics by IFNGS and baseline disease activity.Methods SPOCS (NCT03189875) is an international study of patients with SLE according to Systemic Lupus International Collaborating Clinics (SLICC)/American College of Rheumatology (ACR) criteria. Enrolled patients from 135 centres in 8 countries were followed biannually for <= 3 years from June 2017 to November 2022. Baseline demographics, disease characteristics, organ system involvement/damage and flares were analysed descriptively according to SLE Disease Activity Index-2000 score (SLEDAI-2K <10/>= 10) and IFNGS status (high/low).Results The study population (n=823) was 93.2% female, with mean (SD) age 45.3 (13.9) years and 11.1 (9.2) years since diagnosis; 52.4% had baseline SLICC/ACR Damage Index score >= 1. Patients with SLEDAI-2K scores >= 10 (241 of 584, 41.3%) vs <10 were younger (mean 42.8 (13.7) vs 46.6 (14.2) years; nominal p=0.001), had shorter SLE duration (10.4 (8.6) vs 12.4 (9.6) years; nominal p=0.012) and more severe flares (12.9% vs 5.3%; nominal p=0.001). IFNGS-high patients (522 of 739, 70.6%) were younger than IFNGS-low patients at first SLE manifestation (30.0 (12.7) vs 36.8 (14.6) years; nominal p<0.001). Proportions of IFNGS-high patients differed according to race (nominal p<0.001), with higher proportions among Asian (83.3%) and black (86.5%) versus white patients (63.5%). Greater proportions of IFNGS-high versus IFNGS-low patients had haematological (12.6% vs 4.1%), immunological (74.4% vs 45.6%) or dermal (69.7% vs 62.2%) involvement.Conclusions We identified key characteristics of patients with high disease activity and/or elevated type I IFN signalling, populations with SLE with high unmet needs. Baseline SLEDAI-2K >= 10 was associated with shorter disease duration and more severe flares. IFNGS-high patients were younger at diagnosis and had distinct patterns of organ involvement, compared with IFNGS-low patients.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Systemic lupus erythematosus (SLE) disease characteristics associated with the type I interferon gene signature: Baseline data of the SLE prospective observational cohort study (SPOCS)
    Hammond, Edward R.
    Aringer, Martin
    Arnaud, Laurent
    Peschken, Christine
    Knagenhjelm, Jacob
    Barut, Volkan
    Wang, Xia
    Desta, Barnabas
    Tummala, Raj
    Ginkel, David
    Furie, Richard
    Morand, Eric F.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 493 - 493
  • [2] SYSTEMIC LUPUS ERYTHEMATOSUS DISEASE CHARACTERISTICS ASSOCIATED WITH THE TYPE I INTERFERON GENE SIGNATURE: BASELINE DATA OF THE SLE PROSPECTIVE OBSERVATIONAL COHORT STUDY (SPOCS)
    Hammond, Edward R.
    Aringer, Martin
    Arnaud, Laurent
    Peschken, Christine
    Knagenhjelm, Jacob
    Barut, Volkan
    Wang, Xia
    Desta, Barnabas
    Tummala, Raj
    Ginkel, David
    Furie, Richard
    Morand, Eric F.
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 139 - 139
  • [3] Study protocol for the international Systemic Lupus Erythematosus Prospective Observational Cohort Study (SPOCS): understanding lupus and the role of type I interferon gene signature
    Hammond, Edward R.
    Tummala, Raj
    Berglind, Anna
    Syed, Farhat
    Wang, Xia
    Desta, Barnabas
    Nab, Henk
    BMJ OPEN, 2020, 10 (09):
  • [4] Clinical and Patient-reported Outcomes in Systemic Lupus Erythematosus: An Analysis of the SLE Prospective Observational Cohort Study (SPOCS) US Data
    Furie, Richard
    Binka, Mawuena
    Atefi, Gelareh
    Chen, Stephanie Y.
    Ding, Bo
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 4907 - 4909
  • [5] Disease Activity Progression in Systemic Lupus Erythematosus: An Analysis of the SLE Prospective Observational Cohort Study (SPOCS)
    Morand, Eric
    Furie, Richard
    Peschken, Christine
    Aringer, Martin
    Arnaud, Laurent
    Desta, Barnabas
    Een, Tina Grunfeld
    Sorrentino, Alessandro
    Chen, Stephanie
    Ding, Bo
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 4484 - 4486
  • [6] Organ Damage Progression in Systemic Lupus Erythematosus: An Analysis of the SLE Prospective Observational Cohort Study (SPOCS)
    Furie, Richard
    Morand, Eric
    Peschken, Christine
    Aringer, Martin
    Arnaud, Laurent
    Desta, Barnabas
    Een, Tina Grunfeld
    Sorrentino, Alessandro
    Chen, Stephanie
    Ding, Bo
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 4552 - 4554
  • [7] ASSOCIATION OF PATIENT-REPORTED OUTCOMES WITH TYPE I INTERFERON GENE SIGNATURE FROM THE INTERNATIONAL SYSTEMIC LUPUS ERYTHEMATOSUS PROSPECTIVE OBSERVATIONAL COHORT STUDY (SPOCS)
    Aringer, M.
    Arnaud, L.
    Peschken, C.
    Furie, R.
    Morand, E. F.
    Seo, C.
    Rapsomaniki, E.
    Hedberg, J.
    Knagenhjelm, J.
    Een, T. Grunfeld
    Desta, B.
    Tummala, R.
    Sorrentino, A.
    Stirnadel-Farrant, H.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 648 - 649
  • [8] Real-World Treatment Patterns in Patients with Systemic Lupus Erythematosus: An Analysis of the SLE Prospective Observational Cohort Study (SPOCS)
    Aringer, Martin
    Arnaud, Laurent
    Furie, Richard A.
    Morand, Eric
    Peschken, Christine
    Desta, Barnabas
    Rapsomaniki, Eleni
    Hedberg, Jonatan
    Een, Tina Grunfeld
    Sorrentino, Alessandro
    Ghia, Canna
    Chen, Stephanie
    Ding, Bo
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 1172 - 1174
  • [9] Real-world treatment patterns and clinical characteristics in patients with moderate-to-severe systemic lupus erythematosus: an analysis of the SLE Prospective Observational Cohort Study (SPOCS)
    Aringer, Martin
    Arnaud, Laurent
    Furie, Richard A.
    Morand, Eric F.
    Peschken, Christine
    Hoi, Alberta
    Desta, Barnabas
    Hedberg, Jonatan
    Een, Tina Grunfeld
    Sorrentino, Alessandro
    Kielar, Danuta
    Tummala, Raj
    Chen, Stephanie
    Ding, Bo
    LUPUS SCIENCE & MEDICINE, 2025, 12 (01):
  • [10] Outcomes of neuropsychiatric events in systemic lupus erythematosus based on clinical phenotypes; prospective data from the Leiden NP SLE cohort
    Magro-Checa, C.
    Beaart-van de Voorde, L. J. J.
    Middelkoop, H. A. M.
    Dane, M. L.
    van der Wee, N. J.
    van Buchem, M. A.
    Huizinga, T. W. J.
    Steup-Beekman, G. M.
    LUPUS, 2017, 26 (05) : 543 - 551